Myositis‐Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality
Arthritis & Rheumatology · 2024
DOI: 10.1002/art.42813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Matthew A Sherman und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland. Hauptthemen laut MEDLINE: Autoantibodies, Myositis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, NIEHS NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Objective
Myositis‐associated autoantibodies (MAAs) have been associated with overlap myositis, certain disease manifestations such as interstitial lung disease (ILD), and worse prognosis in the idiopathic inflammatory myopathies. MAAs overall remain largely uncharacterized in patients with juvenile‐onset myositis. Moreover, it is unknown whether the number of MAAs is associated with disease severity.
Methods
Patients with juvenile myositis in cross‐sectional natural history studies who underwent testing for myositis autoantibodies were included. Demographics, myositis autoantibodies, clinical characteristics, medications received, and outcomes of those with and without MAAs were compared. Multivariable logistic regression was performed to determine whether the number of MAAs detected was associated with severe disease features.
Results
Among 551 patients, 36% had an MAA and 13% had more than one MAA. Among those who were MAA positive, there was a higher frequency of overlap myositis (18% vs 5.9%, P < 0.001). MAA positivity was associated with certain clinical features, including Raynaud phenomenon (odds ratio [OR] 2.44, 95% confidence interval [CI] 1.41–4.28) and ILD (OR 3.43, 95% CI 1.75–6.96), as well as a chronic disease course (OR 1.72, 95% CI 1.10–2.72) and mortality (OR 3.76, 95% CI 1.72–8.43). The number of MAAs was also associated with mortality (OR 1.83, 95% CI 1.16–2.86).
Conclusion
MAAs were prevalent in a large cohort of patients with juvenile myositis. ILD, refractory disease, and mortality were associated with MAA positivity. Prospective studies are needed to determine whether early detection of MAAs may lead to improved outcomes for patients with juvenile myositis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
- National Institute of Environmental Health Sciences, NIH, Bethesda, Maryland.
- Oklahoma Medical Research Foundation, Oklahoma City.
- Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City.
- Duke University School of Medicine, Durham, North Carolina.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, and Johns Hopkins University School of Medicine, Baltimore, Maryland.
ORCID-Profile: Matthew A Sherman, Andrew L Mammen, Lisa G Rider
Förderung
- NIAMS NIH HHS
- NIEHS NIH HHS
- Intramural NIH HHS
- NIH
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute of Environmental Health Sciences
- National Institutes of Health
Zitieren
APA
Sherman, M. A., Noroozi Farhadi, P., Pak, K., Trieu, E. P., Sarkar, K., Targoff, I. N., Neely, M. L., Mammen, A. L., Rider, L. G., & Childhood Myositis Heterogeneity Collaborative Study Group (2024). Myositis‐Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality. Arthritis & Rheumatology. https://doi.org/10.1002/art.42813
Vancouver
Sherman MA, Noroozi Farhadi P, Pak K, Trieu EP, Sarkar K, Targoff IN, et al. Myositis‐Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality. Arthritis & Rheumatology. 2024. doi:10.1002/art.42813
BibTeX
@article{Sherman2024,
author = {Sherman, Matthew A and Noroozi Farhadi, Payam and Pak, Katherine and Trieu, Edward P and Sarkar, Kakali and Targoff, Ira N and Neely, Megan L and Mammen, Andrew L and Rider, Lisa G and Childhood Myositis Heterogeneity Collaborative Study Group, Childhood Myositis Heterogeneity Collaborative Study Group},
title = {Myositis‐Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality},
journal = {Arthritis & Rheumatology},
year = {2024},
doi = {10.1002/art.42813}
}
EUVIMED